Who Supplies Aspirin to India from THAILAND

Importing finished pharmaceutical formulations containing Aspirin into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the foreign manufacturer and the product be registered. The foreign manufacturer must possess a valid manufacturing or wholesale drug license from their home country. The product must be registered with CDSCO, which involves submitting an application along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration process typically takes several months, depending on the completeness of the application and the evaluation process. For formulations under HS Code 30049062, specific requirements include compliance with the Indian Pharmacopoeia standards and submission of batch-wise stability data. An Import License from the Directorate General of Foreign Trade (DGFT) is also required, which necessitates obtaining an Importer Exporter Code (IEC) and fulfilling other DGFT formalities. The timeline for obtaining the import drug registration and license can vary but generally spans several months.

Imported finished pharmaceutical formulations containing Aspirin must undergo quality testing to ensure they meet Indian standards. Batch-wise testing is mandatory, and each batch must be accompanied by a Certificate of Analysis (CoA) issued by the manufacturer. The CoA should confirm that the product complies with the specifications outlined in the Indian Pharmacopoeia. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's stability under Indian climatic conditions. Upon arrival at Indian ports, customs drug inspectors conduct inspections to verify the authenticity of the documents and the quality of the products. If any discrepancies or quality issues are identified, the batch may be detained, and further testing may be required. Failure to meet the required standards can result in rejection of the batch and potential penalties for the importer.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements between India and Thailand have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline the import process for Thai manufacturers. Additionally, the CDSCO has updated guidelines for the registration of imported drugs, emphasizing the need for comprehensive stability data and adherence to Indian pharmacopoeia standards. These changes aim to enhance the quality and safety of imported pharmaceutical products.

India imports finished Aspirin formulations to meet the demand for specific dosage forms and branded products not manufactured domestically. The domestic pharmaceutical industry may lack the capacity to produce certain specialized formulations, leading to reliance on imports. The market size for Aspirin formulations in India is substantial, with a growing demand for both over-the-counter and prescription products. Imports play a crucial role in fulfilling this demand, especially for high-quality and branded Aspirin formulations.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049062 is 10%. In addition to BCD, the Social Welfare Surcharge (SWS) is applicable, calculated as a percentage of the BCD. The Integrated Goods and Services Tax (IGST) is also levied on imported goods, including pharmaceutical products. Anti-dumping duties may apply if the Directorate General of Trade Remedies (DGTR) determines that imports are being dumped in the Indian market. Exemption notifications may apply under specific conditions, such as for products imported for charitable purposes or under certain trade agreements. The total landed duty percentage combines BCD, SWS, and IGST, impacting the final cost of imported products.

India sources finished Aspirin formulations from Thailand due to competitive advantages such as the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Thai manufacturers may offer unique formulations or packaging that are not produced domestically. Other suppliers, including China, Germany, and the United States, also export Aspirin formulations to India. Thailand's share in the Indian market is influenced by factors such as product quality, pricing, and regulatory compliance.

India imports finished Aspirin formulations from Thailand due to strategic reasons such as the availability of patented formulations, specialized dosage forms, and technology-licensed products. Specific formulations that Thailand supplies, which India does not manufacture, include certain branded products and unique dosage forms. These imports fulfill market demands that are not met by domestic production capabilities.

When compared to other origins like China, the European Union, and the United States, Thailand offers competitive advantages in terms of price, quality, regulatory compliance, and reliability. Thai manufacturers adhere to international quality standards and offer products at competitive prices. The regulatory compliance and reliability of Thai suppliers make them a preferred choice for Indian importers seeking consistent quality and timely delivery.

Indian importers face several supply chain risks when sourcing finished pharmaceutical formulations from Thailand. Single-source dependency can lead to supply disruptions if the supplier faces issues. Currency fluctuations between the Thai Baht and the Indian Rupee can impact costs. Regulatory changes in either country can affect import procedures and costs. Quality incidents, such as batch rejections, can lead to financial losses and reputational damage. Shipping disruptions, including port congestion or logistical challenges, can delay deliveries. Past shortages have occurred due to unforeseen events affecting production or shipping.